Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)

Andrea De Giglio 1,2, Laura Mezquita 1,3,4, Edouard Auclin 5, Félix Blanc-Durand 1, Mariona Riudavets 1,5, Caroline Caramella 6, Gala Martinez 1, Jose Carlos Benitez 1, Patricia Martin-Romano 7, Lamiae El-Amarti 1, Lizza Hendriks 1,8, Roberto Ferrara 1,9, Charles Naltet 1, Pernelle Lavaud 1, Anas Gazzah 7, Julien Adam 10, David Planchard 1, Nathalie Chaput 11,12 and Benjamin Besse 1,13,*

1 Cancer Medicine Department, Gustave Roussy, 94805 Villejuif, France; andrea.degiglio@studio.unibo.it (A.D.G.); LMEZQUITA@clinic.cat (L.M.); gala.martinez@juntadeandalucia.es (G.M.); Josecarlos.BENITEZ-MONTANEZ@gustaveroussy.fr (J.C.B.); LAMIAE.EL-AMARTI@gustaveroussy.fr (L.E.-A.); lizza.hendriks@mumc.nl (L.H.); Roberto.Ferrara@istitutotumori.mi.it (R.F.); charles.naltet@gustaveroussy.fr (C.N.); PERNELLE.LAVAUD@gustaveroussy.fr (P.L.); david.planchard@gustaveroussy.fr (D.P.)

2 Department of Specialized, Experimental and Diagnostic Medicine, S.Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, 40126 Bologna, Italy

3 Medical Oncology Department, Hospital Clinic, 08036 Barcelona, Spain

4 Laboratory of Translational Genomics and Targeted therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain

5 Medical and Thoracic Oncology Department, Georges Pompidou Hospital, 75015 Paris, France; edouard.auclin@aphp.fr

6 Radiology Department, Gustave Roussy, 94805 Villejuif, France; caroline.caramella@gustaveroussy.fr

7 Early Drug Development Department, Gustave Roussy, 94805 Villejuif, France; Patricia.MARTIN-ROMANO@gustaveroussy.fr (P.M.-R.); Anas.GAZZAH@gustaveroussy.fr (A.G.)

8 Department of pulmonary diseases, GROW-School for Oncology and developmental biology, Maastricht UMC+, 6229 Maastricht, The Netherlands

9 Thoracic Oncology Unit, Medical Oncology Department Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133 Milano, Italy

10 Department of Pathology, Gustave Roussy, 94805 Villejuif, France; julien.adam@gustaveroussy.fr

11 Laboratory of Immunomonitoring in Oncology and CNRS-UMS 3655 and INSERM-US23, Gustave Roussy, 94805 Villejuif, France; chaput-gras.nathalie@gustaveroussy.fr

12 Universite Paris-Saclay, Faculte de Pharmacie, 92296 Chatenay-Malabry, France

13 Universite Paris-Saclay, Faculte de Medecine, 94276 Le Kremlin Bicetre, France

* Correspondence: benjamin.besse@gustaveroussy.fr

Received: 5 September 2020; Accepted: 29 September 2020; Published: 30 September 2020

Simple Summary: Recently, the introduction of immunotherapy radically changed the therapeutic algorithm of non-small-cell lung cancer as an upfront or secondary strategy. Unfortunately, the small amount of patient benefits from immune-checkpoint inhibitors (ICI) and the prognostic role of concomitant treatments are a burning open issue. The use of steroids was associated with poor outcomes during ICI. We investigated the impact of intercurrent steroids, according to clinical indication, which is actually unclear. Interestingly, the use of intercurrent steroids given for cancer-unrelated symptoms has no survival impact on our study cohort.

Abstract: Background: Baseline steroids before ICI have been associated with poor outcomes, particularly when introduced due to cancer symptoms. Methods: Retrospective analysis of
advanced NSCLC patients treated with ICI. We collected the use of intercurrent steroids (≥10 mg of prednisone-equivalent) within the first eight weeks of ICI. We correlated steroid use with patient outcomes according to the indications. Results: 413 patients received ICI, 299 were steroids-naïve at baseline. A total of 49 patients received intercurrent steroids (16%), of whom 38 for cancer-related symptoms and 11 for other indications, such as immune-related events. Overall, median (m) progression-free survival (PFS) was 1.9 months (mo.) [95% CI, 1.8-2.4] and overall survival (OS) 10 mo. [95% CI, 8.1–12.9]. Intercurrent steroids under ICI correlated with a shorter PFS/OS (1.3 and 2.3 mo. respectively, both \( p < 0.0001 \)). Intercurrent steroids for cancer-related symptoms correlated with poorest mPFS [1.1 mo.; 95% CI, 0.9–1.5] and mOS [1.9 mo.; 95%CI, 1.5–2.4; \( p < 0.0001 \)]. No mOS and mPFS differences were found between cancer-unrelated-steroid group and no-steroid group. Steroid use for cancer-related symptoms was an independent prognostic factor for poor PFS [HR 2.64; 95% CI, 1.2–5.6] and OS [HR 4.53; 95% CI, 1.8–11.1], both \( p < 0.0001 \). Conclusion: Intercurrent steroids during ICI had no detrimental prognostic impact if the indication was unrelated to cancer symptoms.

**Keywords:** non-small cell lung cancer; immunotherapy; steroids

### 1. Introduction

The clinical development of immune-checkpoint inhibitors (ICI) has changed the paradigm of treatment for patients with non-small cell lung cancer (NSCLC) [1]. However, only a limited part of patients benefits from ICI, rising up the need for affordable biomarkers and different therapeutic strategies. Although evaluating the tumor membrane expression of programmed death-ligand 1 (PD-L1) has become mandatory for newly diagnosed advanced NSCLC [2], the ICI as single-agent can achieve satisfying responses regardless of the PD-L1 status in the pretreated population [1].

In addition to tumor biomarkers, other clinical factors have been associated with ICIs outcomes. These factors can potentially influence ICIs efficacy, such as age, Eastern Cooperative Organization performance status (ECOG PS), and concomitant therapies.

Systemic steroids impair the immune system at multiple levels, ranging from the inhibition of acute inflammation to a long-term immunomodulatory effect, and constitute the cross-sectional backbone of the immunosuppressive therapy [3].

In cancer patients, steroids are largely used for treatment of cancer-related symptoms, such as dyspnea, fatigue, anorexia, and symptomatic brain metastasis [4–6]. Other conditions, not strictly related to cancer spread, may also require steroids prescription at the beginning or during the anticancer treatments: Exacerbations of chronic diseases (e.g., chronic obstructive pulmonary disease (COPD), rheumatic diseases, etc.) or toxicities developed under therapies, such as immune-related adverse events (irAEs) [7].

Baseline use of ≥ 10 mg of prednisone equivalents was associated with poor outcomes to ICIs in a large retrospective cohort of pretreated advanced NSCLC, independently from ECOG PS, presence of brain metastasis, or smoking status [8]. In a similar retrospective work, the early introduction of steroids showed a detrimental impact on survival outcomes [9]. Based on these, the use of ≥ 10 mg of prednisone equivalents under ICI has been limited and it is still a classical baseline exclusion criterion from clinical trials.

However, a recent retrospective study revealed that the negative impact of baseline steroids was only observed among patients treated for cancer-related symptoms, more likely related to the palliative condition of this population [10]. To date, the clinical relevance of the initiation of steroids under ICI according to the reason for prescription remains unknown.
In this study, we aimed to assess the impact on patient outcomes of the intercurrent introduction of steroids (within the first eight weeks) under ICI therapy, and according to the reason of prescription in a large cohort of pretreated advanced NSCLC patients under ICI.

2. Results

A total of 413 patients treated with ICIs were enrolled (Figure S1). The median age was 63 years (range 30–92), most of them were male (66%), current or former smokers (91%), with non-squamous histology (76%) and ECOG PS ≤ 1 (77%). PD-L1 status was available for 52% of patients, of which 149 (69%) had ≥ 1% PD-L1 expression and 68 (31%) were negative. All patients received single-agent ICI but 29 (combination with anti-EGFR antibody n = 18, immunotherapy investigational drugs n = 8, radiotherapy n = 3). Baseline characteristics of the overall population are summarized in Table 1. With a median follow-up of 24.4 months [95% CI, 19.5 to 32.4], median PFS and OS were 1.9 months [95% CI, 1.77 to 2.40] and 10 months [95% CI, 8.11 to 12.91], respectively.

### Table 1. Baseline characteristics of the study population.

| Characteristic       | Subgroup     | Overall          | Steroid-Free Population | Baseline Steroids | Intercurrent Steroids Non-Cancer-Related | Intercurrent Steroids Cancer-Related | p Value |
|----------------------|--------------|------------------|-------------------------|-------------------|-----------------------------------------|-------------------------------------|---------|
|                      | (N = 413)    | (N = 250)        | (N = 114)               | (N = 11)          | (N = 38)                                |                                     |         |
| Age                  | Median, range| 63 (30-92)       | 63 (30-92)              | 62 (34.85)        | 68 (57.75)                              | 63 (42.80)                          | 0.38    |
| Gender               | F            | 140 (34%)        | 88 (35%)                | 33 (29%)          | 6 (55%)                                 | 13 (34%)                            | 0.41    |
|                      | M            | 273 (66%)        | 162 (66%)               | 81 (71%)          | 5 (45%)                                 | 25 (66%)                            |         |
| Smoking history      | current      | 127 (31%)        | 81 (33%)                | 31 (27%)          | 4 (36%)                                 | 11 (30%)                            | 0.95    |
|                      | former       | 239 (59%)        | 139 (57%)               | 74 (66%)          | 6 (55%)                                 | 20 (55%)                            |         |
|                      | never smoker | 39 (9%)          | 25 (10%)                | 8 (7%)            | 1 (9%)                                  | 5 (14%)                             |         |
|                      | missing      | 8                | 5                       | 1                 | 0                                       | 2                                   |         |
| Histology            | Non squamous | 314 (76%)        | 195 (78%)               | 82 (72%)          | 8 (72.7%)                               | 29 (76%)                            | 0.83    |
|                      | Squamous     | 99 (24%)         | 55 (22%)                | 32 (28%)          | 3 (27.2%)                               | 9 (24%)                             |         |
| PD-L1                | negative     | 67 (32%)         | 42 (32%)                | 18(31%)           | 2 (25%)                                 | 5 (36%)                             | 0.93    |
|                      | positive ≥ 1%| 145 (68%)        | 89 (68%)                | 41 (69%)          | 6 (75%)                                 | 9 (64%)                             |         |
|                      | missing      | 201              | 119                     | 55                | 3                                       | 24                                  |         |
| Stage                | IIIB         | 3 (0.7%)         | 3 (1.2%)                | 0                 | 0                                       | 0                                   | 0.59    |
|                      | IV           | 410 (99.3%)      | 247 (98.8%)             | 114               | 11                                      | 38                                  |         |
| Metastatic sites     | ≤2           | 188 (46%)        | 123 (49%)               | 47 (41%)          | 5 (45.4%)                               | 13 (34%)                            | 0.21    |
|                      | >2           | 224 (54%)        | 126 (51%)               | 67 (59%)          | 6 (54.5%)                               | 25 (66%)                            |         |
|                      | missing      | 1                | 1                       | 1                 | 0                                       | 0                                   |         |
| Brain metastases     | No           | 286 (69%)        | 192 (77%)               | 56 (49%)          | 6 (55%)                                 | 32 (84%)                            | 0.12    |
|                      | Yes          | 127 (31%)        | 58 (23%)                | 58 (51%)          | 5 (45%)                                 | 6 (16%)                             |         |
| Liver metastases     | No           | 311 (75%)        | 188 (75%)               | 86 (75%)          | 10 (90%)                                | 27 (71%)                            | 0.44    |
|                      | Yes          | 102 (25%)        | 62 (25%)                | 28 (25%)          | 1 (10%)                                 | 11 (29%)                            |         |
| Line of immunotherapy| 1-2         | 259 (63%)        | 167 (67%)               | 58 (51%)          | 6 (55%)                                 | 28 (74%)                            | 0.46    |
|                      | >2           | 154 (37%)        | 83 (33%)                | 56 (49%)          | 5 (45%)                                 | 10 (26%)                            |         |
| ECOG PS              | 0-1          | 313 (77%)        | 207 (84%)               | 72 (64%)          | 8 (72.7%)                               | 26 (70%)                            | 0.09    |
|                      | ≥2           | 95 (23%)         | 40 (16%)                | 41(36%)           | 5 (27.2%)                               | 11 (30%)                            |         |
|                      | missing      | 10               | 3                       | 5                 | 0                                       | 1                                   |         |

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status.
2.1. Steroids in the Study Population

At baseline, 114 patients (28%) received steroids. In the baseline steroids-naïve group of patients (N = 299, 72%), 49 (12%) started them within the first eight weeks of ICI therapy. Among them, 38 patients (9%) received steroids for cancer-related indications and 11 (2%) for non-cancer-related indications.

Baseline characteristics of the study population according to the intercurrent steroids are summarized in Table 1. The intercurrent steroid population was most commonly associated with ECOG PS2 and more than two metastatic sites. Steroids were given orally (80%), with only 20% intravenously prescribed.

The main indications for cancer-related indications were dyspnea (50%), symptomatic brain metastasis (16%), cancer-related pain (8%) (Table S1). The main indication for non-cancer-related indications were immune-related adverse events (irAEs) (54.6%) and pneumonia/re-exacerbation of COPD (27.1%) (Table S2).

The median daily dose of prednisone equivalent was 40 mg for cancer-related symptoms (range 5–225, IQR 17.5–60) and 50 mg for unrelated indications (range 10–90, IQR 20–60) (Figure S2). The median time on treatment was eight weeks for cancer-related (range 0.1–53, IQR 4.3–16.6) and five weeks for unrelated indications (range 0.1–121, IQR 0.7–26.1) (Figure S2).

2.2. Steroids and Clinical Outcomes

Steroids at baseline were associated with poor PFS and OS (both \( p < 0.0001 \)), with a median PFS of 1.68 months [95% CI, 1.4 to 2.0], and a median OS of 4.20 months [95% CI, 2.6 to 9.3].

Intercurrent steroids were also associated with poor PFS and OS (both \( p < 0.0001 \)), with a median PFS of 1.3 months [95% CI, 0.9 to 1.6], and a median OS of 2.23 months [95% CI, 1.94 to 3.91]. Figure 1 shows the survival outcomes according to the steroid therapy in the study population.

![Figure 1](image-url)
tumor-related indication compared with the group of patients receiving intercurrent steroids for tumor-unrelated indications and with the group of steroid-free patients. (A) shows overall survival (OS) in baseline-treated patients with steroids (green line), steroids free population (blue line), and intercurrent steroids treated patients (red line). (B) shows OS in steroid-free population (blue line), intercurrent steroid treatment for cancer-related indications (orange line), and intercurrent steroids treatment for non-cancer-related indications (green line) (cancer-related vs. non-cancer-related, \( p < 0.002 \)). (C) As in (A) but progression-free survival (PFS), (D) as in (B) but PFS (cancer-related vs. non-cancer-related \( p = 0.05 \)).

Considering the reason of prescription, in the intercurrent steroids group for cancer-related symptoms, the median OS was 1.9 months [95% CI, 1.5 to 2.4] versus 13.4 months [95% CI, 4.3 to not reached (NR)] in the intercurrent steroid group for non-cancer-related symptoms [95% CI, 4.3 to NR]. In terms of PFS, the median was 1.2 months [95% CI, 0.85 to 1.51] versus 2.3 months [95% CI, 1.22 to not reached (NR)] in intercurrent steroids group for non-cancer-related symptoms (both \( p < 0.0001 \)). (Figure 1). In the steroids-naïve population \( (N = 250, 61\%) \), neither at baseline nor intercurrent, the median PFS was 2.6 months [95% CI, 2.2 to 3.9] and a median OS of 13.8 months. [95% CI, 11.4 to 18], with no differences compared to intercurrent steroids group for non-cancer-related symptoms.

Figure 2 shows the clinical course of patients receiving intercurrent steroids for cancer-related (Figure S3) and unrelated (Figure S4) indications during the first year of follow-up.

**Figure 2.** Swimmers plot detailing progression survival (PFS) and overall survival (OS) after one year of follow-up of patients receiving intercurrent steroids for cancer-related (blue) and not related (green) indications. Abbreviations: Immune-related adverse events (irAEs); progressive disease (PD).
Intercurrent steroids for cancer-related symptoms was an independent factor for PFS [HR 2.64; 95% CI, 1.24 to 5.61; \( p < 0.0001 \)] and OS [HR 4.53; 95%CI, 1.8 to 11.1]; \( p < 0.0001 \) in the multivariate analysis, including age, gender, smoking status, histology, ECOG PS, and antibiotics at baseline (Table 2). The ECOG PS \( \geq 2 \) and a precedent/concomitant use of antibiotics were independently associated with poor PFS (respectively HR 1.5, (95% CI, 1.1 to 2.2) \( p = 0.01 \), and 1.3, (95% CI, 1 to 1.8), \( p = 0.01 \)) and OS (respectively HR 2.1, (95% CI 1.4 to 3.1), \( p < 0.0001 \), and 1.6, (95% CI, 1.1 to 2.1) \( p = 0.003 \) (Table 2 and Table S3).

| Table 2. Multivariate analysis for PFS and OS. |
|-----------------------------------------------|
| **Multivariate Analysis** | **PFS** | **OS** |
| | **HR** | **95% CI** | **p Value** | **HR** | **95% CI** | **p Value** |
| Age | | | | | | |
| \( \leq 65 \text{ years} \) | 1 | - | - | 1 | - | - |
| >65 years | 0.97 | 0.74–1.27 | 0.85 | 1.1 | 0.80–1.50 | 0.53 |
| Smoking status | | | | | | |
| Never/former smoker | 1 | - | - | 1 | - | - |
| Smoker | 0.6 | 0.40–0.89 | 0.01 | 0.88 | 0.56–1.37 | 0.58 |
| Histology | | | | | | |
| Non-squamous | 1 | - | - | 1 | - | - |
| Squamous | 1.11 | 0.81–1.53 | 0.48 | 1.25 | 0.86–1.80 | 0.22 |
| Immunotherapy line | | | | | | |
| \( \leq 2 \) | 1 | - | - | 1 | - | - |
| >2 | 1.28 | 0.97–1.68 | 0.07 | 1.23 | 0.89–1.68 | 0.19 |
| Number of met. Sites | | | | | | |
| \( \leq 2 \) | 1 | - | - | 1 | - | - |
| >2 | 1.15 | 0.87–1.51 | 0.31 | 1.26 | 0.92–1.72 | 0.14 |
| ECOG PS | | | | | | |
| 0–1 | 1 | - | - | 1 | - | - |
| \( \geq 2 \) | 1.56 | 1.10–2.21 | 0.01 | 2.15 | 1.46–3.12 | <0.0001 |
| Use of antibiotics | | | | | | |
| No | 1 | - | - | 1 | - | - |
| Yes | 1.39 | 1.05–1.83 | 0.01 | 1.59 | 1.17–2.17 | 0.003 |
| Intercurrent steroids introduction | | | | | | |
| Non-cancer-related | 1 | - | - | 1 | - | - |
| No steroids | 1.02 | 0.51–2.02 | 1.25 | 0.54–2.88 |
| Cancer-related | 2.64 | 1.24–5.61 | <0.0001 | 4.53 | 1.84–11.12 | <0.0001 |

Legend: Cox proportional hazard regression analysis of progression-free survival and overall survival according to age, smoking status, histology, immunotherapy line of treatment, number of metastatic sites, ECOG PS, use of antibiotics and intercurrent introduction of corticosteroids for cancer-related symptoms. Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; CI, confidence interval.

3. Discussion

As far as we are aware, this is the first study reporting that intercurrent steroids under ICI have no detrimental impact on clinical outcomes when prescribed for non-cancer-related symptoms. In our work, 12% of the patients were treated with intercurrent steroids and experienced poor outcomes (mPFS 1.3 months; mOS 2.2 months). Nevertheless, this negative impact was mainly associated with the prescription for cancer-related symptoms, suggesting that this can be more likely related to the palliative condition of this population, and not with the drug-effect on their immune system. No differences were observed between intercurrent steroids group for cancer-unrelated symptoms (mPFS 2.2 months; mOS 13.4 months) and the no-steroids group (mPFS 2.6 months; mOS 13.8 months).
Daily dose of $\geq 10$ mg of prednisone equivalent has been historically considered an exclusion criterion for clinical trials, mainly based on the increased rate of infections in other chronic diseases, but not on a specific contraindication for cancer patients [11–13]. In advanced NSCLC patients, we reported that $\geq 10$ mg use of daily prednisone equivalent at baseline was strongly associated with poor ICI outcomes in a large cohort of 640 patients [8]. However, patients treated with steroids were more commonly associated with poor prognostic factors, such as brain metastasis or ECOG PS $\geq 2$, that may also play a role in the negative impact reported.

Based on this hypothesis, Ricciuti et al. studied the clinical impact of baseline-steroids, with the same threshold, according to the reason of prescription in 650 advanced NSCLC patients [10]. In this work, the authors observed that the negative impact of baseline-steroids on outcomes was not confirmed for the subgroup treated for cancer-unrelated indications, questioning the negative predictive role suggested for steroids on ICI treatment [10], which is in line with our data.

Although some previous studies have also investigated the role of intercurrent steroids treatment. Fucà et al. [9] reported worse outcomes in 23% of patients treated with intercurrent steroids (first 28 days) retrospectively studied on 151 advanced NSCLC patients treated with ICI. Similarly, Drakaki et al. [14] reported that baseline-steroids and intercurrent steroids up to 30 days under ICI (30%) were associated with poor outcomes in a cohort of 862 NSCLC patients. In these two studies, the reason for prescription was not analyzed and the threshold for daily prednisone equivalents differed. Interestingly, Pennel et al. reported at the 2019 World Conference on Lung Cancer (WCLC) the impact of intercurrent steroids on the real-world CancerLinq Discovery Database in 11,143 advanced NSCLC treated with ICI [15]. Among them, 1581 received intercurrent steroids ($\geq 10$ mg of prednisone equivalent) within the first 30 days, associated with poor OS. However, when the survival was adjusted by clinical characteristics (age/gender/PS/brain metastasis) no differences were observed in OS, consistent with our findings. The lack of detailed clinical data about the reason for prescription and the appurtenance of a poor prognosis subgroup may confound this statement. In fact, only one experience evidenced this conflict dissecting the clinical indication as palliative or not palliative [10].

Recently, a meta-analysis explored the impact of steroids across 16 studies with melanoma and NSCLC patients [16]. Overall, the patients treated with steroids had a higher risk of both progression and death, but only the intercurrent steroids for palliative purposes were related to the greater risk of death compared to patients receiving steroids for brain metastasis or irAEs. However, the clinical indication was not formally investigated in the majority of the studies enrolled in this meta-analysis. Conversely, the use of steroids for the management of irAEs did not increase the risk of death, as previously described.

The main biological hypothesis of the detrimental impact of steroids under ICI is based on the well-known immunosuppressive effects on both acute and chronic inflammation. The activation of glucocorticoid intracellular receptor (GR) inhibits the innate and adaptive immune response via genomic and non-genomic pathways [2]. Nevertheless, an increasing amount of evidence also shows that steroids can positively induce the innate response stimulating the expression of pattern recognition receptors (PRR), complement components [17], and the production of several cytokines and their receptors such as IL-1, IL-6, TNF, and IFN$\gamma$ [18]. In light of these data, Cain et al. [17] proposed a biphasic model of immune systems’ regulation under the stimulus of steroids that may promote an immune response earlier but shorter with respect to a condition of endogenous steroids deficiency. Whether this model is applicable in cancer patients treated concomitantly with ICI and steroids remains an open issue but evocates possible different biological scenarios, in particular, involving the innate system and myeloid lines.

Consistently, as previously reported, steroids can induce increased absolute neutrophil count (ANC) [19–21], and it has been even associated with the polarization of macrophages to M2 macrophages, with pro-tumoral functions [22]. Thus, the global impact of steroids on the immune context of the patients should be further explored.
Although it was not the primary goal of the project, our study showed that the introduction of antibiotic therapy within two months before and one month after the ICI was independently associated with poor outcomes at the multivariate analysis. Interestingly, antibiotics may alter gut microbiota, as suggested by pre-clinical studies conducted on mice models [23]. Moreover, several retrospective analyses [24,25] confirmed the detrimental role of antibiotics in survival outcomes in cohorts of advanced NSCLCs treated with anti-PD-(L)1 inhibitors, albeit the assessment of the underlying mechanisms is still an open issue.

Finally, our findings also confirmed that a deteriorated performance status at baseline (≥2) correlated with poor survival outcomes, as previously described [26]. Notably, Facchinetti et al. evidenced that only a disease burden-induced poor ECOG PS (vs. comorbidities-induced) was independently related with a bad prognosis [27].

Our study has several limitations worthy of discussion. Firstly, the analysis had the intrinsic limitation of a monocentric retrospective experience, with some missing data (e.g., PD-L1 status). In addition, response assessment was not homogenously performed following RECIST v.1.1 criteria with a dedicated radiologist, but the response rate was investigator-assessed, thus resulting less accurate for PFS analysis, the reason why we considered it as secondary endpoint. Finally, the small size of the sample of patients treated for non-cancer-related indications did not allow postulating definitive conclusions.

Despite these limitations, we believe that our work helps to lighten the role of intercurrent steroids in patients treated with ICI. In particular, that the negative impact on clinical outcomes of intercurrent-steroids, as at baseline, is more likely related to the palliative condition of the patients rather than a drug-effect. Thus, steroid prescription should not be avoided under ICI if it is indicated.

4. Materials and Methods

4.1. Patients

We conducted a retrospective study of advanced NSCLC patients treated with PD-(L)1 ICI, as monotherapy or in combination with other drugs (e.g., ipilimumab), at Gustave Roussy (GR), between February 2013 and September 2018. Patients treated with a combination of chemotherapy and ICI were not included in this study.

Clinical and biological data were collected from electronic medical records. PD-L1 expression was assessed by IHC on tumor cells, according to standard practice. PD-L1 expression ≥1% was considered positive. This study was approved by the Internal Review Board at GR. Steroids at baseline and/or within the first eight weeks of ICI (= intercurrent steroids) were retrospectively collected, including type of drug, daily dose, duration of therapy, way of administration, and reason for prescription. We defined the use of steroid therapy if the was at least one-day prescription of ≥ 10 mg of prednisone-equivalent.

4.2. Statistical Analysis

Median (interquartile-range) values and proportions (percentage) were provided for the description of continuous and categorical variables, respectively. Mean and proportions were compared using t-test (or Anova if appropriate) and chi2-test (or Fisher’s exact test, if appropriate), respectively. The primary outcome was overall survival (OS), secondary end-point was progression-free survival (PFS). OS was defined as the time between the start of ICI treatment and death. PFS was defined as the time from the start of ICI treatment to the first radiological or clinical progression according to RECIST 1.1 or per investigator discretion, whichever occurred first. Patients who were still alive at data lock (May 2019) were censored at last contact. Median OS and PFS were estimated with the Kaplan Meier method and compared with the Log Rank test. The median follow-up was calculated with the reverse Kaplan Meier method.

The association between clinical, biological, pharmacological variables and survival endpoints was explored with a Cox model regression. First, a univariate analysis was performed for both survival
endpoints. All variables reaching a p value < 0.1 or considered as clinically relevant were included in a multivariable model. p value < 0.05 were considered statistically significant. Statistical analyses were performed using R-Studio.

5. Conclusions

Our data suggest that the intercurrent steroids of a daily dose of ≥10 mg of prednisone equivalent within the first eight weeks of ICI have no detrimental impact on prognosis if the indication is not related to cancer symptoms. A larger prospective validation of our retrospective data is needed.

Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/10/2827/s1.

Figure S1: Flowchart of the study. Figure S2: Box and whiskers plot describing daily dose (A) and duration of steroid treatment (B) per indication. Figure S3: Swimmers plot detailing progression survival (PFS) and overall survival (OS) after 1 year of follow-up of patients receiving intercurrent steroids for cancer-related indications. Figure S4: Swimmers plot detailing progression survival (PFS) and overall survival (OS) after 1 year of follow-up of patients receiving intercurrent steroids for cancer-unrelated indications. Table S1: Cancer-related indications for corticosteroids administrations are listed with cumulative dosages. Table S2: Non-cancer-related indications for steroids administrations are listed with cumulative dosages. Table S3: Baseline Characteristics of study population according to antibiotic prescription.

Author Contributions: A.D.G.: conceptualization, data curation, writing-original draft. L.M.: conceptualization, methodology, writing-review & editing. E.A.: formal analysis. F.B.-D.: investigation. M.R.: writing-review & editing. C.C.: methodology. G.M.: investigation. J.C.B.: investigation. P.M.-R.: supervision. L.E.-A.: data curation. L.H.: writing-review & editing. R.F.: writing-review & editing. C.N.: resources. P.L.: data curation. A.G.: visualization. J.A.: visualization. D.P.: methodology, supervision. N.C.: methodology, supervision. B.B.: methodology, supervision, project administration. All authors have read and agreed to the published version of the manuscript.

Funding: Andrea De Giglio received support from the Erasmus Traineeship Program. Laura Mezquita received support from the 2018 IASLC Research Fellowship Award, ESMO Translational Research Fellowship 2019 and SEOM Retorno de Investigadores 2019. Role of funding source: No specific sponsorship for this study. Support received for a fellowship period at Gustave Roussy Cancer Center.

Acknowledgments: We drafted this paper with the unconditioned collaboration of Sarah McKenzie as medical writer.

Conflicts of Interest: A.D.G.: nothing to declare. L.M.: Sponsored Research: Bristol-Myers Squibb, Boehringer Ingelheim, Amgen. Travel, Accommodations, Expenses: Roche. Mentorship program with key opinion leaders: funded by AstraZeneca. E.A.: Travel expenses: Mundipharma. Lectures and educational activities: Bristol-Myers Squibb, Tecnofarma, Roche. Travel, Accommodations, Expenses: Roche. Mentorship program with key opinion leaders: funded by AstraZeneca. F.B.-D.: nothing to declare. M.R.: nothing to declare. C.C.: Advisory board: BMS: MSD, Roche, Amgen, Astra Zeneca. G.M.: nothing do declare. J.C.B.: nothing to declare. P.M.-R.: Principal/sub-Investigator of Clinical Trials for Abbvie, Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bbva, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Blueprint Medicines, Boehringer, Boston Pharmaceuticals, Bristol-Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Forma Therapeutics, Gamamabs, Genentech, Glaxosmithkline, H3 Biomedicine, Hoffmann La Roche Ag, Imcheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Janssens Cilag, Janssen Research Foundation, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Onyx Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Xencor. Research Grants from Astrazeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merc, Novartis, Pfizer, Roche, Sanofi Non-financial support (drug supplied) from Astrazeneca, Bayer, BMS, Boringher Ingelheim, Medimmune, Merc, NH TherAGuiX, Pfizer, Roche. L.E.-A: nothing to declare. L.H.: None related to current manuscript, outside of current manuscript: research funding Roche, Boehringer Ingelheim, AstraZeneca (all institution), advisory board: Boehringer, BMS, Lilly, Roche, Pfizer, Takeda, MSD, Amgen, Boehringer Ingelheim (all institution), speaker: MSD, travel/conference reimbursement: Roche, BMS (self); mentorship program with key opinion leaders: funded by AstraZeneca; fees for educational webinars: Quadia (self), interview sessions funded by Roche (institution). R.F.: Advisory board: MSD. Travel Grant: Pfizer. C.N.: nothing to declare. P.L.: Travel accomodations: Astellas-Pharma, Astra Zeneca, Ipsen, Janssens Oncology, Mundi Pharma. A.G.: Travel: accommodation, congress registration expenses from Boehringer Ingelheim, Novartis, Pfizer, Roche. Consultant/Expert role for Novartis. Principal/sub-Investigator of Clinical Trials for Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bbva, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai
Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Exelixis, Forma, Gamababs, Genentech, Inc., Gilead Sciences, Inc, Glaxosmithkline, Glenmark Pharmaceuticals, H3 Biomedicine, Inc, Hoffmann La Roche Ag, Incyte Corporation, Innate Pharma, Iris Servier, Janssen, Kura Oncology, Kyowa Kirin Pharm, Lilly, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octomet Oncology Nv, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Rigontec Gmbh, Roche, Sanofi Aventis, Sierra Oncology, Taiho Pharma, Tesaro, Inc, Tioma Therapeutics, Inc., Xencor. Research Grants from AstraZeneca, BMS, Boehringer Ingelheim, Janssen, Merck, Merck, Novartis, Pfizer, Roche, Sanofi. Non-financial support (drug supplied) from AstraZeneca, Bayer, BMS, Böringer Ingelheim, Johnson & Johnson, Lilly, Medimmun, Merck, NH TherAGuiX, Pfizer, Roche. J.A.: Advisory Board: AstraZeneca, Bayer. Honorarium: MSD, BMS. D.P.: Consulting: advisory role or lectures: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Daichii Sankyo, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche, Samsung Honoraria: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Celgene, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peer CME, Roche. Clinical trials research: AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Medimmun, Sanofi-Aventis, Taiho Pharma, Novocure, Daichii Sankyo. Travel, Accommodations, Expenses: AstraZeneca, Roche, Novartis, prIME Oncology, Pfizer. N.C.: Sponsored Research at Gustave Roussy Cancer Center AstraZeneca, BMS, GSK, Roche, Sanofi, Cyture Pharma, Gilead. B.B.: Sponsored Research at Gustave Roussy Cancer Center. Abbvie, Amgen, AstraZeneca, BeIGene, Blueprint Medicines, BMS, Boehringer Ingelheim, Celgene, Cristal Therapeutics, Daichi-Sankyo, Eli Lilly, GSK, Ignyta, IPSEN, Inivata, Janssen, Merck KGaA, MSD, Nektar, Onxeo, OSE immunotherapeutics, Pfizer, Pharma Mar, Roche-Genentech, Sanofi, Servier, Spectrum Pharmaceuticals, Takeda, Tiziana Pharma, Toler Pharma. 

References

1. Remon, J.; Passiglia, F.; Ahn, M.J.; Barlesi, F.; Forde, P.M.; Garon, E.B.; Gettinger, S.; Goldberg, S.B.; Herbst, R.S.; Horn, L.; et al. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology. J. Thorac. Oncol. 2020, 15, 914–947. [CrossRef] [PubMed]

2. Reck, M.; Rodriguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csoszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tarfeshi, A.; Cuffe, S.; et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. N. Engl. J. Med. 2016, 375, 1823–1833. [CrossRef] [PubMed]

3. Coutinho, A.E.; Chapman, K.E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol. Cell Endocrinol. 2011, 335, 2–13. [CrossRef]

4. Haywood, A.; Duc, J.; Good, P. Systemic steroids for the management of cancer-related breathlessness (dyspnoea) in adults. Cochrane Database Syst. Rev. 2019, 20, 2. [CrossRef]

5. Yennurajalingam, S.; Bruera, E. Review of clinical trials of pharmacologic interventions for cancer-related fatigue: Focus on psychostimulants and steroids. Cancer J. 2014, 20, 319–324. [CrossRef]

6. Ryken, T.C.; McDermott, M.; Robinson, P.D. The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2010, 96, 103–114. [CrossRef]

7. Haanen, J.B.A.G.; Carbonnel, F.; Robert, C. On behalf of the ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017, 28, iv119–iv142. [CrossRef]

8. Arbour, K.C.; Mezquita, L.; Long, N. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer. J. Clin. Oncol. 2018. [CrossRef]

9. Fucà, G.; Galli, G.; Poggi, M. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 2019, 4, e000457. [CrossRef]

10. Ricciuti, B.; Dahlberg, S.E.; Adeni, A. Immune Checkpoint Inhibitor Outcomes for Patients With Non–Small-Cell Lung Cancer Receiving Baseline Steroids for Palliative Versus Nonpalliative Indications. J. Clin. Oncol. 2019. [CrossRef]

11. Youssef, J.; Novosad, S.A.; Winthrop, K.L. Infection Risk and Safety of Corticosteroid Use. Rheum Dis. Clin. N. Am. 2016, 42, 157. [CrossRef] [PubMed]

12. Dixon, W.G.; Suisse, S.; Hudson, M. The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: Systematic review and meta-analyses. Arthritis Res. Ther. 2011, 13, R139. [CrossRef] [PubMed]
13. Stuck, A.E.; Minder, C.E.; Frey, F.J. Risk of infectious complications in patients taking glucocorticoids. *Rev. Infect. Dis.* 1989, **11**, 954–963. [CrossRef] [PubMed]

14. Drakaki, A.; Luhn, P.; Wakelee, H.; Dhillon, P.K.; Kent, M.; Shim, J.; Degaonkar, V.; Hoang, T.; McNally, V.; Chui, S.Y.; et al. Association of Systemic Corticosteroids with Overall Survival in Patients Receiving Cancer Immunotherapy for Advanced Melanoma, Non-Small Cell Lung Cancer or Urothelial Cancer in Routine Clinical Practice. *Ann. Oncol.* 2019, **30**, xi16–xi17. [CrossRef]

15. Patil, P.; Jia, X.; Hobbs, B.; Pennell, N. The impact of early steroids on clinical outcomes in patients with advanced nsclc treated with immune checkpoint inhibitors-a cancerlinq cohort. *World Lung Cancer Conf.* 2019. [CrossRef]

16. Petrelli, F.; Signorelli, D.; Ghidini, M.; Ghidini, A.; Pizzutilo, E.G.; Ruggieri, L.; Cabiddu, M.; Borgonovo, K.; Dognini, G.; Brighenti, M.; et al. Association of Steroids Use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. *Cancers* 2020, **12**, 546. [CrossRef]

17. Cain, D.W.; Cidlowski, J.A. Immune regulation by glucocorticoids. *Nat. Rev. Immunol.* 2017, **17**, 233–247. [CrossRef]

18. Wiegens, G.J.; Reul, J.M. Induction of cytokine receptors by glucocorticoids: Functional and pathological significance. *Trends Pharmacol Sci.* 1998, **19**, 317–321. [CrossRef]

19. Gu, X.B.; Tian, T.; Tian, X.J.; Zhang, X.J. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: A meta-analysis. *Sci. Rep.* 2015, **5**, 12493. [CrossRef]

20. Mezquita, L.; Auclain, E.; Ferrara, R. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. *JAMA. Oncol.* 2018, **4**, 351–357. [CrossRef]

21. Ronchetti, S.; Ricci, E.; Migliorati, G. How Glucocorticoids Affect the Neutrophil Life. *Int. J. Mol. Sci.* 2018, **19**, 4090. [CrossRef] [PubMed]

22. Sica, A.; Mantovani, A. Macrophage plasticity and polarization: In vivo veritas. *J. Clin. Investig.* 2012. [CrossRef] [PubMed]

23. Wang, Y.; Ma, R.; Liu, F.; Lee, S.A.; Zhang, L. Modulation of gut microbiota: A novel paradigm of enhancing the efficacy of programmed death-1 and programmed death ligand-1 blockade therapy. *Front Immunol.* 2018, **9**. [CrossRef] [PubMed]

24. Pinato, D.J.; Howlett, S.; Ottaviani, D.; Urus, H.; Patel, A.; Mineo, T.; Brock, C.; Power, D.; Hatcher, O.; Falconer, A.; et al. Association of Prior Antibiotic Treatment with Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients with Cancer. *JAMA. Oncol.* 2019, **5**, 1774–1778. [CrossRef] [PubMed]

25. Derosa, L.; Hellmann, M.D.; Spaziano, M.; Halpenny, D.; Fidelle, M.; Rizvi, H.; Long, N.; Plodkowski, A.J.; Arbour, K.C.; Chaft, J.E.; et al. Negative Association of Antibiotics on Clinical Activity of Immune Checkpoint Inhibitors in Patients with Advanced Renal Cell and Non-Small-Cell Lung Cancer. *Ann. Oncol.* 2018, **29**, 1437–1444. [CrossRef]

26. Passaro, A.; Spitaleri, G.; Gyawali, B.; de Marinis, F. Immunotherapy in non–small-cell lung cancer patients with performance status 2: Clinical decision making with scant evidence. *J. Clin. Oncol.* 2019, **37**, 1863–1867. [CrossRef]

27. Facchinetti, F.; Mazzaschi, G.; Barbieri, F.; Passiglia, F.; Mazzoni, F.; Berardi, R.; Proto, C.; Cecere, F.L.; Pilotto, S.; Scotti, V.; et al. First-Line Pembrolizumab in Advanced Non–Small Cell Lung Cancer Patients with Poor Performance Status. *Eur. J. Cancer.* 2020, **130**, 155–167. [CrossRef]